IMMUNDIAGNOSTIK, AG Patent applications |
Patent application number | Title | Published |
20160025748 | NON-OXIDIZED, BIOLOGICAL ACTIVE PARATHYROID HORMONE DETERMINES MORTALITY IN HEMODIALYSIS PATIENTS - A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. FIG. | 01-28-2016 |
20150038411 | RELAXIN FOR TREATING PATIENTS AFFLICTED OF IMPAIRED GLUCOSE TOLERANCE - A pharmaceutical composition for treatment for of r afflicted or in risk of becoming of impaired glucose tolerance (IGT) and/or type-2 it comprising an effective amount of relaxin for protecting beta-cells and beta-cell function against the effects of high blood glucose (glucotoxicity). Treatment of persons of disglycaemias, and protection of beta cells of the islets of Langerhans and beta-cell function in patients having type-2 diabetes, is diclosed. | 02-05-2015 |
20150017738 | MEANS AND METHODS OF MEASURING PARATHYROID HORMONE IN PATIENTS SUFFERING FROM OXIDATIVE STRESS - Method for obtaining an antibody or antibody fragment to a conformational epitope specific for oxidized, inactive human parathyroid hormone and fragments thereof; a method for removal of oxidized, inactive human parathyroid hormone from a sample of body fluid; methods of determining the concentration of active parathyroid hormone in a sample, and an in vitro method of diagnosis of renal failure or secondary hyperthyroidism in patients on dialysis. The antibody is obtained by immunizing an animal with an immunogen containing parathyroid hormone or fragment thereof oxidized at methionines at positions 8, 18 or both; and a recovering of antibodies; whereby the complementary determining region of the antibody or antibody fragment or single chain antibody specifically recognizes a conformational epitope (antigenic determinant) which is a tertiary structure and only present on oxidized parathyroid hormone and fragments thereof only but not regular bioactive human parathyroid hormone, while the binding surface to the complementary binding region does not include any one of the oxidized methionines of human parathyroid hormone. | 01-15-2015 |
20140072988 | DETERMINATION OF VITAMIN D METABOLITES IN DRIED BLOOD - Method and test kit for quantitative determination of Vitamin D metabolites in blood, wherein a predetermined amount of blood is pre-analytically immobilised on a solid sorption material. Thereby, hemolysis of the blood has no effect on the analysis of vitamin D metabolites. For quantitative analysis the dried blood spot on the sorption material is dissolved with an aqueous solvent buffer containing detergent, pH 7.0 to 10.0, and the vitamin D metabolites are eluted with a protic organic solution having a permittivity of less than 35. The eluate is analysed for vitamin D metabolites using conventional methods. | 03-13-2014 |
20110003311 | DIAGNOSIS SYSTEM FOR DETERMINING THE BIOLOGICALLY EFFECTIVE PARATHYROID HORMONE ACTIVITY IN A SAMPLE - Diagnosis system or immunoassay for the determination of the effective parathyroid hormone activity in a sample, and for a diagnosis and treatment of calcium metabolism disturbances, osteopathies and hyper- or hypoparathyroidisms. The parathyroid hormone activity is measured with the aid of an antibody which binds to an epitope in the region of the receptor binding structure | 01-06-2011 |